Journal article
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Abstract
BACKGROUND: Previous meta-analyses suggest that treatment with erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) increases the risk for death. Additional randomized trials have been recently completed.
PURPOSE: To summarize the effects of ESA treatment on clinical outcomes in patients with anemia and CKD.
Authors
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V
Journal
Annals of Internal Medicine, Vol. 153, No. 1, pp. 23–33
Publisher
American College of Physicians
Publication Date
July 6, 2010
DOI
10.7326/0003-4819-153-1-201007060-00252
ISSN
1056-8751